vs

Side-by-side financial comparison of CLEANSPARK, INC. (CLSK) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

CLEANSPARK, INC. is the larger business by last-quarter revenue ($181.2M vs $151.7M, roughly 1.2× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -209.0%, a 203.5% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.6%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-198.1M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 106.4%).

CleanSpark, Inc. is a U.S.-headquartered sustainable technology company operating two core business segments: low-carbon Bitcoin mining powered primarily by renewable and stranded energy resources, and end-to-end microgrid design, deployment, and operation services for commercial, industrial, and public sector clients across North America.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CLSK vs TARS — Head-to-Head

Bigger by revenue
CLSK
CLSK
1.2× larger
CLSK
$181.2M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+116.8% gap
TARS
128.4%
11.6%
CLSK
Higher net margin
TARS
TARS
203.5% more per $
TARS
-5.5%
-209.0%
CLSK
More free cash flow
TARS
TARS
$211.0M more FCF
TARS
$13.0M
$-198.1M
CLSK
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
106.4%
CLSK

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLSK
CLSK
TARS
TARS
Revenue
$181.2M
$151.7M
Net Profit
$-378.7M
$-8.4M
Gross Margin
47.2%
Operating Margin
-174.7%
-5.3%
Net Margin
-209.0%
-5.5%
Revenue YoY
11.6%
128.4%
Net Profit YoY
-253.5%
63.8%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLSK
CLSK
TARS
TARS
Q4 25
$181.2M
$151.7M
Q3 25
$118.7M
Q2 25
$102.7M
Q1 25
$78.3M
Q4 24
$66.4M
Q3 24
$89.3M
$48.1M
Q2 24
$104.1M
$40.8M
Q1 24
$111.8M
$27.6M
Net Profit
CLSK
CLSK
TARS
TARS
Q4 25
$-378.7M
$-8.4M
Q3 25
$-12.6M
Q2 25
$-20.3M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$-62.2M
$-23.4M
Q2 24
$-236.2M
$-33.3M
Q1 24
$126.7M
$-35.7M
Gross Margin
CLSK
CLSK
TARS
TARS
Q4 25
47.2%
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
36.0%
Q2 24
56.6%
Q1 24
69.3%
Operating Margin
CLSK
CLSK
TARS
TARS
Q4 25
-174.7%
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-73.5%
-52.3%
Q2 24
-239.2%
-81.6%
Q1 24
-136.5%
Net Margin
CLSK
CLSK
TARS
TARS
Q4 25
-209.0%
-5.5%
Q3 25
-10.6%
Q2 25
-19.8%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
-69.6%
-48.7%
Q2 24
-226.9%
-81.6%
Q1 24
113.4%
-129.4%
EPS (diluted)
CLSK
CLSK
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.30
Q2 25
$-0.48
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLSK
CLSK
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$458.1M
$417.3M
Total DebtLower is stronger
$1.8B
$72.4M
Stockholders' EquityBook value
$1.4B
$343.4M
Total Assets
$3.3B
$562.2M
Debt / EquityLower = less leverage
1.29×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLSK
CLSK
TARS
TARS
Q4 25
$458.1M
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$121.2M
$317.0M
Q2 24
$126.1M
$323.6M
Q1 24
$298.5M
Total Debt
CLSK
CLSK
TARS
TARS
Q4 25
$1.8B
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$7.2M
$71.7M
Q2 24
$1.3M
$71.6M
Q1 24
$5.1M
$29.9M
Stockholders' Equity
CLSK
CLSK
TARS
TARS
Q4 25
$1.4B
$343.4M
Q3 25
$335.1M
Q2 25
$332.6M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$1.8B
$237.5M
Q2 24
$1.4B
$252.2M
Q1 24
$1.5B
$275.2M
Total Assets
CLSK
CLSK
TARS
TARS
Q4 25
$3.3B
$562.2M
Q3 25
$534.6M
Q2 25
$495.0M
Q1 25
$500.8M
Q4 24
$377.0M
Q3 24
$2.0B
$376.3M
Q2 24
$1.5B
$376.8M
Q1 24
$1.5B
$349.3M
Debt / Equity
CLSK
CLSK
TARS
TARS
Q4 25
1.29×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.00×
0.30×
Q2 24
0.00×
0.28×
Q1 24
0.00×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLSK
CLSK
TARS
TARS
Operating Cash FlowLast quarter
$-161.1M
$19.3M
Free Cash FlowOCF − Capex
$-198.1M
$13.0M
FCF MarginFCF / Revenue
-109.3%
8.6%
Capex IntensityCapex / Revenue
20.4%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-626.9M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLSK
CLSK
TARS
TARS
Q4 25
$-161.1M
$19.3M
Q3 25
$18.3M
Q2 25
$-29.4M
Q1 25
$-20.7M
Q4 24
$-22.2M
Q3 24
$-233.7M
$-8.7M
Q2 24
$-58.4M
$-14.4M
Q1 24
$-44.8M
$-37.8M
Free Cash Flow
CLSK
CLSK
TARS
TARS
Q4 25
$-198.1M
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-299.8M
$-8.9M
Q2 24
$-68.7M
$-15.4M
Q1 24
$-60.3M
$-38.0M
FCF Margin
CLSK
CLSK
TARS
TARS
Q4 25
-109.3%
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-335.8%
-18.6%
Q2 24
-66.0%
-37.8%
Q1 24
-54.0%
-137.5%
Capex Intensity
CLSK
CLSK
TARS
TARS
Q4 25
20.4%
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
74.0%
0.6%
Q2 24
9.9%
2.5%
Q1 24
13.8%
0.6%
Cash Conversion
CLSK
CLSK
TARS
TARS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons